Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
EcoR1 Capital, LLC (CIK 1587114) reported $2.36B across 24 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: ZYME ($575.2M, 24.41%), ANAB ($437.0M, 18.55%), JAZZ ($322.6M, 13.69%), CNTA ($254.6M, 10.81%), CRNX ($155.7M, 6.61%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ZYME | ZYMEWORKS INC | $575.2M | 24.41% | 23.0M | Hold |
| 2 | ANAB | ANAPTYSBIO INC | $437.0M | 18.55% | 7.9M | Hold |
| 3 | JAZZ | JAZZ PHARMACEUTICALS PLC | $322.6M | 13.69% | 1.7M | Hold |
| 4 | CNTA | CENTESSA PHARMACEUTICALS PLC | $254.6M | 10.81% | 6.4M | Added |
| 5 | CRNX | CRINETICS PHARMACEUTICALS IN | $155.7M | 6.61% | 4.3M | Hold |
| 6 | AKTIS ONCOLOGY INC | $86.3M | 3.66% | 4.8M | New | |
| 7 | ORIC | ORIC PHARMACEUTICALS INC | $85.2M | 3.62% | 6.7M | Hold |
| 8 | CGON | CG ONCOLOGY INC | $74.6M | 3.17% | 1.1M | Added |
| 9 | CRSP | CRISPR THERAPEUTICS AG | $66.1M | 2.80% | 1.4M | Hold |
| 10 | ETON | ETON PHARMACEUTICALS INC | $53.6M | 2.27% | 2.2M | Added |
| 11 | GLPG | GALAPAGOS NV | $50.0M | 2.12% | 1.7M | Hold |
| 12 | XNCR | XENCOR INC | $26.3M | 1.12% | 2.2M | Trimmed |
| 13 | NGNE | NEUROGENE INC | $25.6M | 1.09% | 1.3M | Hold |
| 14 | BRIDGEBIO ONCOLOGY THERAPEUT | $25.3M | 1.07% | 2.8M | Hold | |
| 15 | MBX | MBX BIOSCIENCES INC | $23.2M | 0.98% | 777,000 | Trimmed |
| 16 | RLAY | RELAY THERAPEUTICS INC | $19.0M | 0.80% | 1.9M | New |
| 17 | ZBIO | ZENAS BIOPHARMA INC | $15.4M | 0.66% | 789,500 | Hold |
| 18 | ERAS | ERASCA INC | $14.6M | 0.62% | 900,000 | New |
| 19 | EIKON THERAPEUTICS INC | $7.8M | 0.33% | 732,606 | New | |
| 20 | REPL | REPLIMUNE GROUP INC | $7.7M | 0.32% | 1.0M | New |
| 21 | ZURA | ZURA BIO LTD | $7.0M | 0.30% | 1.2M | New |
| 22 | PHAT | PHATHOM PHARMACEUTICALS INC | $6.9M | 0.29% | 625,000 | New |
| 23 | MREO | MEREO BIOPHARMA GROUP PLC | $4.4M | 0.19% | 13.4M | Added |
| 24 | PRLD | PRELUDE THERAPEUTICS INC | $3.2M | 0.14% | 947,049 | New |
| 25 | STOK | STOKE THERAPEUTICS INC | $3.3M | 0.14% | 100,000 | New |
Source: SEC Form 13F filings · as of 2026-03-31